Bright Minds Biosciences Inc. (DRUG) Financials

DRUG Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 223.8 million 2.7 million
Dec. 31, 2025 66.3 million 1.2 million
Sept. 30, 2025 60.6 million 1.7 million
June 30, 2025 38.6 million 490828

DRUG Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -6.8 million 864110
Dec. 31, 2025 -4.2 million 937421
Sept. 30, 2025 -910650 767751
June 30, 2025 -2.6 million 971150

DRUG Net Income

No data available :(

DRUG Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 221.9 million - 58897
Dec. 31, 2025 65.0 million - 76514
Sept. 30, 2025 59.5 million - 90329
June 30, 2025 37.8 million - 103650

DRUG Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 6.9 million
Dec. 31, 2025 5.7 million
Sept. 30, 2025 5.1 million
June 30, 2025 5.2 million

DRUG Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 2 9.5 million 1.6 million -
Dec. 31, 2025 - 4.1 million 794474 72285
Sept. 30, 2025 - 3.4 million 543230 109480
June 30, 2025 2 2.0 million 435047 82811

DRUG Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 14435
Dec. 31, 2025 - 14421
Sept. 30, 2025 - 8770
June 30, 2025 - 8553

DRUG

Price: $58.96

52 week price:
23.18
123.75

Earnings Per Share: -2.49 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 141500

Market Capitalization: 574.9 million

Links: